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Abstract 
Clozapine is the first atypical antipsychotic, and improves positive and negative 
symptoms of many patients with schizophrenia resistant to treatment with other 
antipsychotic agents. Clozapine induces minimal extrapyramidal side effects, but is more 
often associated with seizures. A large number of studies have been conducted to 
elucidate pharmacological profiles of clozapine and its major active metabolite, 
N-desmethylclozapine (NDMC). However, there are only a limited number of 
electrophysiological studies examining their effects on synaptic transmission. In this 
study, we examined effects of clozapine and NDMC on synaptic transmission by 
measuring inhibitory and excitatory postsynaptic currents in rat cultured hippocampal 
neurons. We found that clozapine and NDMC have qualitatively similar actions. They 
depressed the inhibitory transmission at 1-30 M, and the excitatory transmission at 30 
M, the former being much more sensitive. The depression of IPSCs by 30 M of these 
drugs was associated with an increase in the paired-pulse ratio. The GABA-induced 
currents were suppressed by these drugs, but less sensitive than IPSCs. The 
AMPA-induced currents were slightly potentiated by these drugs at 30 M. At 30 M, 
clozapine and NDMC slightly suppressed Ca2+ and Na+ channels. These results strongly 
suggest that clozapine and NMDC depress the inhibitory synaptic transmission mainly by 
antagonizing postsynaptic GABAA receptors, but at higher concentrations additionally by 
acting on presynaptic site, possibly in part through inhibition of presynaptic Ca2+ and Na+ 
channels. Preferential depression of inhibitory synaptic transmission by clozapine and 
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1. Introduction 
Clozapine is the first atypical antipsychotic, and improves positive and negative 
symptoms of many patients with schizophrenia whose illness is resistant to treatment 
with other antipsychotic agents (Kane et al., 1988; Leucht et al., 2003). Clozapine induces 
minimal extrapyramidal side effects, but is more often associated with seizures (Devinsky 
and Pacia, 1994; Haddad and Dursun, 2008; Pacia and Devinsky, 1994; Wong and Delva, 
2007). It exhibits complex pharmacological properties, and interacts with various types of 
metabotropic receptors for neurotransmitters including dopamine, serotonin, 
norepinephrine, histamine and acetylcholine (Correll, 2010; Weiner et al., 2004). It has 
also been reported that clozapine interacts with GABAA receptor in a 
receptor-subtype-dependent manner (Korpi et al., 1995; Squires and Saederup, 1998), 
suggesting a possible role of clozapine as a direct modulator of synaptic transmission. 
Actually, an electrophysiological study demonstrated that clozapine depressed 
GABAergic inhibitory synaptic transmission through antagonism of GABAA receptors at 
synapses on ventral tegmental area (VTA) neurons (Michel and Trudeau, 2000). Because 
this effect was observed at concentrations that could occur in the brain of the patients with 
clozapine treatment, the authors suggested that this depression of GABAergic 
transmission might contribute to the therapeutic actions of clozapine and/or its 
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side-effects, such as seizures. However, it is not clear whether the sensitivity of 
GABAergic transmission to clozapine is unique to VTA neurons or a common feature 
throughout the brain. 
 N-desmethylclozapine  (NDMC) is a major active metabolite of clozapine, and 
has unique pharmacological profiles (Mendoza and Lindenmayer, 2009). Recent studies 
with animal models have suggested that NDMC might contribute to the unique efficacy 
of clozapine (Bishara and Taylor, 2008). NDMC can interacts with various types of 
metabotropic receptors for monoamines and acetylcholine (Lameh et al., 2007). In 
addition, NDMC is also reported to interact with GABAA receptors (Wong et al., 1996), 
suggesting that GABAergic transmission might be sensitive to NDMC as well as 
clozapine. Despite a large number of pharmacological studies on NMDC, there is no 
electrophysiological evidence for direct action of NDMC on synaptic transmission.  
 In the present study, we examined effects of clozapine and NDMC on 
excitatory and inhibitory synaptic transmissions in cultured hippocampal neurons. The 
hippocampus contains glutamatergic and GABAergic neurons, but not monoaminergic 
neurons. Thus, the basal levels of monoamines in this culture system should be negligible. 
Using this preparation, we minimized possible indirect effects of the drugs on synaptic 
transmission through well-known antagonistic effects on monoaminergic receptors, 
which might be tonically active and involved in regulation of synaptic transmission. Here 
we provide electrophysiological evidence for direct actions of clozapine and NDMC on 
synaptic transmission through the interactions with postsynaptic GABAA receptors and 
presynaptic mechanisms. Our data clearly show that clozapine and NDMC depress the 
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inhibitory synaptic transmission more effectively than the excitatory one, suggesting that 
the preferential depression of GABAergic transmission might contribute to therapeutic 
actions and/or side-effects of clozapine. 
 
2. Results 
Neurons were whole-cell voltage clamped with patch pipettes. Access resistance, input 
resistance, and holding current at -80 mV in the presence and absence of  3 and 30 M of 
clozapine or NDMC are shown in Table 1. Neurons treated with these drugs exhibited no 
signs of cell damage. To measure synaptic currents, one neuron of a pair was stimulated, 
and inhibitory or excitatory postsynaptic currents (IPSCs or EPSCs) were measured from 
the other neuron at -80 mV. IPSCs and EPSCs show slow and fast decay kinetics, 
respectively, and can be easily discriminated (Fig. 1A). In some experiments, the 
relevance of this criteria was confirmed by examining reversal potentials and sensitivities 
to GABAA and AMPA receptor antagonists, bicuculline and CNQX (Fig. 1B, C). 
 
2.1 Effects on synaptic transmission 
First we examined whether clozapine effectively depresses the inhibitory synaptic 
transmission in hippocampal neurons, as reported in VTA neurons. When the external 
solution containing 30 M of clozapine was bath-applied for 1 min, IPSCs were 
depressed in a reversible manner (Fig. 2A). On average, the IPSC amplitude was 
decreased to 27.8 ± 3.2 % (n=7, p<0.001), and recovered to 91.3 ± 5.0 % of control (n=7, 
p=0.28) (Fig. 2B, 30 Clo). Because synaptic currents of cultured cells have a tendency to 
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rundown even in the absence of drugs, we normalized the value in the presence of drug 
(T) to the mean of the values of control (C) and recovery (R) in each experiment to avoid 
overestimation of drug effect. The data presented in Fig. 2C and similar graphs in the 
following figures were obtained by this means. Each open symbol in Fig. 2C shows the 
data from each neuron pair, and squares and diamond marks indicate the data from 
excitatory and inhibitory postsynaptic neurons, respectively. Open circles are the date 
from unidentified neurons. On average, the IPSC amplitude was decreased to 29.5 ± 
3.8 % of control by 30 M clozapine (p<0.01). As shown in Fig. 2C, clozapine was 
effective irrespective of the type of postsynaptic neurons. Further experiments with lower 
concentrations (1 and 3 M) of clozapine demonstrated that clozapine was effective even 
at 1 M (Fig. 2B, 2C). On average, 1 and 3 M clozapine significantly decreased the 
IPSC amplitude to 89.8 ± 4.0 (n=7, p<0.05) and 82.2 ± 4.0 % (n=9, p<0.05), respectively 
(Fig. 2C). Similar experiments were performed with NDMC, and we found that NDMC 
also suppressed IPSCs in a dose-dependent, and reversible manner (Fig. 2, D-F). On 
average, NDMC decreased the IPSC amplitude to 88.7 ± 2.9 % (n=8, p<0.05) at 1 M,  
77.5 ± 2.4 % (n=7, p<0.01) at 3 M, and 14.6 ± 3.0 % (n=6, p<0.05) at 30 M (Fig. 2F). 
Like clozapine, NDMC was effective irrespective of the type of postsynaptic neurons 
(Fig. 2F). 
 Next we examined effects of clozapine and NDMC on EPSCs. Because 
NMDA-type receptors are expected to be blocked by Mg2+ under our recording 
conditions (-80 mV, 1 mM Mg2+), it is conceivable that EPSCs depend largely on 
AMPA-type glutamate receptors. As expected, we observed that the AMPA receptor 
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antagonist CNQX (25 M) suppressed EPSCs completely (Fig. 1C, 0.4 ± 1.1 %, n=8). 
Compared to IPSCs, EPSCs were much less sensitive to clozapine (Fig. 3, A-C) and 
NDMC (Fig. 3, D-F). Clozapine depressed EPSCs slightly, but significantly, at 30 M 
(83.1 ± 5.7 %, n=9, p<0.05), but ineffective at 3 M (97.5 ± 1.8 %, n=9, p=0.478) (Fig. 
3C).  Similarly, NDMC decreased the EPSC amplitude to 55.4 ± 6.3 % (n=12, P<0.01) at 
30 M, but was without effect at 3 M (100.6 ± 2.1 %, n=9, p=0.65) (Fig. 3F). These 
results clearly show that the inhibitory synaptic transmission is more sensitive to these 
drugs than the excitatory transmission.  
 
2.2 Effects on postsynaptic neurotransmitter receptors 
To test the possibility that these effects on synaptic transmission are caused by direct 
interaction with postsynaptic receptors for neurotransmitters, that is, GABAA and AMPA 
receptors, we examined effects of clozapine and NDMC on these receptors. For 
monitoring the activity of GABAA receptors, the external solution containing 10 M 
GABA was locally applied for 3 sec to the recorded neurons through a puff pipette with 
an interval of 2 min. The GABA-induced currents recorded in these conditions were 
confirmed to be mediated mostly by GABAA receptors by simultaneously treating with 
bicuculline (Fig. 4A, 6.1 ± 1.1 %, n=6). When GABA was locally applied in the presence 
of clozapine or NDMC, GABA-induced currents were significantly reduced (Fig. 4). The 
peak amplitude was decreased to 95.8 ± 1.8 % (n=7, p<0.05), 92.3 ± 3.1 % (n=6, p<0.05) 
and 52.3 ± 5.0 % (n=5, p<0.05) by 1, 3 and 30 M clozapine, respectively (Fig. 4D), and 
93.1 ± 1.8 % (n=6, p<0.05), 87.7 ± 1.0 % (n=7, p<0.01) and 35.2 ± 3.9 % (n=9, p<0.01) 
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by 1, 3 and 30 M NDMC, respectively (Fig. 4H). These data indicate that the 
suppressing effects of clozapine and NDMC on IPSCs can be partly explained by their 
actions on GABAA receptors. However, the effects on GABA-induced currents were 
significantly weaker than the effects on IPSCs for 30 M clozapine (p<0.01) (Fig. 4E), 3 
M NDMC (p<0.01) and 30 M NDMC (p<0.01) (Fig. 4I), suggesting additional 
contribution of presynaptic mechanisms. 
 Effects of the drugs on AMPA receptors were similarly examined by applying 
50 M AMPA. The AMPA-induced currents were confirmed to be blocked by the AMPA 
receptor antagonist CNQX (Fig. 5A, 6.5 ± 3.1 %, n=6). When AMPA was locally applied 
in the presence of 30 M clozapine or NDMC, AMPA-induced currents were slightly, but 
significantly, potentiated (Fig. 5B, D). The current amplitude was 112.8 % ± 1.5 % (n=8, 
p<0.01) and 118.2 ± 4.2 % of control (n=7, p<0.01) in the presence of 30 M clozapine 
(Fig. 5C) and NDMC (Fig. 5E), respectively. These results indicate that suppressing 
effects of clozapine and NDMC on EPSCs cannot be explained by their actions on 
postsynaptic AMPA receptors, suggesting involvement of presynaptic mechanisms. 
  
2.3 Effects on the paired-pulse ratio 
Involvement of presynaptic mechanisms was further demonstrated by measuring the 
paired-pulse (PP) ratio, which is widely used as an index of presynaptic changes. We first 
confirmed that presynaptic suppression induced by the GABAB agonist baclofen, but not 
postsynaptic suppression by the GABAA antagonist bicuculline, is associated with an 
increase in the PP ratio (Fig. 6A). Similarly, we observed that the suppression of IPSCs by 
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30 M clozapine (Fig. 6B) or NDMC was associated with a significant increase in the PP 
ratio (n=6, p<0.05 for clozapine, n=8, p<0.01 for NDMC) (Fig. 6C). At 3 M, clozapine 
and NDNC induced a slight increase in the PP ratio, but this change was not significant 
(n=7, p=0.207 for clozapine, n=8, p=0.066 for NDMC). The suppression of EPSCs by 30 
M NDMC, but not clozapine (n=6, p=0.271), was also associated with a significant 
increase in the PP ratio (n=6, p<0.05) (Fig. 6D). These data strongly suggest that 
presynaptic mechanisms contribute to the suppression of IPSCs by 30 M clozapine and 
NDMC and the suppression of EPSCs by NDMC.  
 
2.4 Effects on voltage-gated ion channels 
Presynaptic suppression might be causes by their action on presynaptic receptors, ion 
channels or some other components involved in transmitter release itself or its 
modulation. In the present study, we examined only their effects on ion channels. We 
measured Ca2+, Na+ and K+ currents activated by depolarizing voltage pulses. The 
Cd2+-sensitive component of the currents induced by depolarizing voltage pulses (from 
-80 mV to -10 mV, 50 ms, 0.1 Hz) under the blockade of Na+ and K+ channels was 
assumed to be Ca2+ current (Fig. 7A, the rightmost trace). Clozapine and NDMC 
significantly decreased the amplitude of Ca2+ currents to 92.8 ± 2.0 % (n=11, p<0.01) and 
82.3 ± 3.8 % (n=11, p<0.01), respectively, at 30 M, but not at 3 M (n=5, p=0.306 for 
clozapine, n=5, p=0.493 for NDMC) (Fig. 7). 
 Inward Na+ currents were measured by applying depolarizing voltage pulses 
(from -80 mV to 0 mV, 5 ms, 0.25 Hz). At 30 M, clozapine and NDMC slightly, but 
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significantly, decreased the peak amplitude of Na+ currents to 91.3 ± 1.5 % (n=6, 
p<0.001) and 86.6 ± 2.1 % (n=6, p<0.001), respectively (Fig. 8). Outward K+ currents 
were measured by applying voltage pulses (from -80 mV to 0 mV, 30 ms, 0.25 Hz) under 
the blockade of Na+ channels. The peak amplitude of outward currents was also slightly 
suppressed by 30 M clozapine (93.9 ± 1.6 %, n=6, p<0.05) and NDMC (96.5 ± 1.2 %, 
n=8, p<0.05) (Fig. 9). We cannot simply assume that these effects on somatic ion 
channels are directly representative of effects on presynaptic ion channels. However, if 
these effects are caused by direct interaction with ion channels, it seems likely that 
clozapine and NDMC act on presynaptic Ca2+ and Na+ channels and thereby influence the 
transmitter release. Of course, we cannot exclude any other possibilities, including 
indirect actions through metabotropic receptors.  
 
3. Discussions 
 In the present study, we found that clozapine and its active metabolite NDMC 
have qualitatively similar actions on synaptic transmission in rat cultured hippocampal 
neurons. These two substances depress both inhibitory and excitatory transmission, the 
former being much more sensitive. Our electrophysiological data strongly suggest that 
these effects on synaptic transmission can be accounted for by their interactions with 
postsynaptic GABAA receptors and some actions on presynaptic site. 
 Depression of inhibitory transmission by clozapine was previously reported in 
rat cultured VTA neurons (Michel and Trudeau, 2000).  The study reported that clozapine 
decreased inhibitory autaptic currents (IACs), which were recorded in single neuron 
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micro-dot cultures, and exogenous GABA-induced currents to approximately the same 
extent, that is, 10 M clozapine decreased IACs by 34 % and GABA-induced currents by 
28 %. Thus, the authors concluded that the effect on GABAergic transmission is 
attributable to its action on postsynaptic GABAA receptors. There is another 
electrophysiological study examining effects of clozapine on inhibitory transmission 
(Gemperle et al., 2003). Using rat brain slices including prefrontal area, inhibitory 
postsynaptic potentials (IPSPs) were recorded from layer V neurons following 
stimulation of layer II. Clozapine failed to affect IPSPs at 30 M, although higher 
concentrations of clozapine (100-300 M) showed a dose-dependent tendency to reduce 
IPSPs without statistical significance. One possibility explaining this apparent 
discrepancy in effect of 10-30 M clozapine is that the clozapine-sensitivity of 
GABAergic synapses is region-specific, and especially high in the VTA. Another 
possibility is that the apparent difference in clozapine sensitivity is due largely to the 
methodological difference, namely culture versus slice preparations. In the present study, 
we used cultured hippocampal neurons, and observed that 3 M and 30 M clozapine 
decreased IPSCs by 18 % and 71 %, respectively (Fig. 2), which are comparable to that 
seen with cultured VTA neurons. Thus, clozapine-induced depression of GABAergic 
transmission at micromolar concentrations is not limited to the VTA, and may be rather 
general phenomenon throughout the brain.  
 There are no electrophysiological studies reporting effects of NDMC on 
inhibitory synaptic transmission, although its interaction with GABAA receptors have 
been suggested by pharmacological studies (Wong et al., 1996). In the binding study 
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using rat brain membranes, NDMC was shown to antagonize GABAA receptors with a 
similar potency to clozapine. Both NDMC and clozapine required micromolar 
concentrations to affect cerebrocortical and hippocampal GABAA receptors. These 
results are consistent with our electrophysiological data for effects of NDMC and 
clozapine on GABA-induced currents. Furthermore, the present study provides the first 
electrophysiological evidence for depression of inhibitory synaptic transmission by 
NDMC. Like clozapine, NDMC was confirmed to depress the inhibitory transmission 
much more effectively than the excitatory one.  
 Effects of clozapine on excitatory synaptic transmission have also been 
examined using electrophysiological methods. In the CA1 area of rat hippocampal slices, 
50 M clozapine induced a transient depression (21 % of control) of extracellular field 
potentials followed by a small augmentation (10 %) (Baskys et al., 1993). In the 
prefrontal cortex of rat brain slices, 10-300 M clozapine had no significant effect on 
excitatory postsynaptic potentials (EPSPs) (Gemperle et al., 2003). In rat prefrontal 
cortical neurons, 50-100 nM clozapine increased the NMDA component of EPSPs 
(Arvanov et al., 1997). The reason for these diverse effects is unclear, but it is likely that 
in slice preparations clozapine might influence the glutamatergic transmission indirectly, 
that is, through modulation of signaling of other neurotransmitters such as dopamine 
(Ninan and Wang, 2003). In the present study, we minimized such an indirect effect by 
using the culture system, and found that clozapine depresses glutamatergic transmission. 
Consistent with our data, inhibition of glutamate release by clozapine is reported in 
synaptosomes purified from rat prefrontal cortex (Yang and Wang, 2005). 
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 We found that higher levels of clozapine and NDMC inhibit voltage-gated Ca2+ 
and Na+ channels, which could cause presynaptic inhibition of synaptic transmission at 
both inhibitory and excitatory synapses. There are some studies reporting effects of 
clozapine on voltage-gated Ca2+ channels. Clozapine inhibited voltage-gated Ca2+ 
channels in adrenal chromaffin cells (Park et al., 2001), native T-type Ca2+ channels in 
human thyroid C cells (Enyeart et al., 1992), and recombinant CaV3.1 T-type Ca2+ 
channels (Choi and Rhim, 2010). The present study demonstrated that native Ca2+ 
channels expressed in central neurons are also sensitive to clozapine, and that NDMC 
again mimics the clozapine’s action. Hippocampal neurons express multiple types of Ca2+ 
channels including P/Q-, N-, R-, L- and T-types. Whether clozapine and NDMC inhibit 
all these channels or certain types selectively remains to be elucidated. 
 The median (10th and 90th percentiles) clozapine and N-desmethylclozapine 
concentrations of plasma samples from clozapine-treated patients were reported to be 
0.41 (0.13-0.98) mg/l and 0.25 (0.0-0.53) mg/l, respectively (Couchman et al., 2010). 
Considering these values and the observations that the concentrations of clozapine and 
NDMC in brain tissue are higher than in serum (Gershkovich et al., 2010; Weigmann et 
al., 1999), the brain concentrations in patients might reach the concentrations used in the 
present study. Thus, it is likely that excitatory/inhibitory balance is disturbed by both 
clozapine and NDMC through rather selective depression of inhibitory synaptic 
transmission, which might be implicated in the therapeutic actions and/or seizures as 
side-effects associated with clozapine-treatment. 
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4. Experimental Procedure 
4.1 Preparation of neurons.  
All experiments were performed according to the guidelines laid down by the animal 
welfare committees of Kanazawa University. Cultured hippocampal neurons were 
prepared from newborn Sprague-Dawley rats, as described previously (Ohno-Shosaku et 
al., 2001). Briefly, cells were mechanically dissociated from the hippocampi and plated 
onto culture dishes (35 mm) pretreated with poly L-ornithine (0.01 %). The cultures were 
kept at 36 C in 5 % CO2 for 8-17 days before use. 
 
4.2 Electrophysiology.  
For measurements of synaptic currents, each neuron of a pair was whole-cell voltage 
clamped at –80 mV using a patch pipette (3 –5 M) filled with a standard internal 
solution containing (in mM) 100 K-gluconate, 15 KCl, 10 HEPES, 10 EGTA, 6 MgCl2, 
4.65 CaCl2, 40 KOH, 5 Na2ATP and 0.2 Na2GTP (pH 7.3, adjusted with KOH). The 
presynaptic neuron was stimulated by applying positive voltage pulses (to 0 mV, 2 ms) at 
0.2 or 0.5 Hz, and inhibitory or excitatory postsynaptic currents (IPSCs or EPSCs) were 
measured from the postsynaptic neuron at -80 mV with a patch-clamp amplifier (EPC9/3, 
HEKA Electronics, Germany). IPSCs and EPSCs are easily distinguished by their decay 
time constants, reversal potentials and sensitivities to GABAA and AMPA receptor 
antagonists (Fig. 1). When postsynaptic neurons formed synapses on presynaptic neurons 
(reciprocal connections) or themselves (autapses), we could identify the type of 
postsynaptic neurons (i.e., excitatory or inhibitory). A standard external solution 
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contained (in mM) 140 NaCl, 2.5 KCl, 2 CaCl2, 1 MgCl2, 10 HEPES and 10 glucose (pH 
7.3, adjusted with NaOH). To minimize spontaneous synaptic currents, 0.5-1 mM 
kynurenic acid was added to the standard external solution. The recording chamber was 
perfused with the kynurenic acid-containing external solution with or without a drug 
(clozapine or NDMC) at a flow rate of 1-3 ml/min. In each experiment, five consecutive 
synaptic currents were averaged before, during and after drug application, and the 
averaged value obtained during application was divided by the mean of the values before 
and after application (Fig. 2C, 2F, 3C, 3F).  
 For measurements of postsynaptic sensitivities to GABA and AMPA, 0.1 M 
tetrodotoxin (TTX) was added to the standard external solution. The TTX-containing 
solution with either 10 M GABA or 50 M AMPA was locally applied for 3 sec through 
a capillary tube (250 m inner diameter) located near the tested neurons with an interval 
of 2 min using a perfusion valve controller (VC-6M, Warner Instruments, CT) (Fig. 4A, 
5A). The applied agonist was rapidly washed out by continuous bath perfusion. The 
agonist-induced inward currents were recorded at -80 mV, using patch pipettes filled with 
the standard internal solution.  
 For measurements of Ca2+ currents, an external solution containing (in mM) 
130 NaCl, 10 TEA-Cl, 2.5 KCl, 2 CaCl2, 1 MgCl2, 1 4-aminopyridine (4-AP) and 10 
HEPES (pH 7.3, adjusted with NaOH) was used. Patch pipettes were filled with a 
solution containing (in mM) 120 CsCl, 30 CsOH, 10 HEPES, 10 EGTA, 5 Na2ATP, 5 
MgCl2 and 1 CaCl2 (pH 7.3, adjusted with CsOH). Voltage-gated Ca2+ channels were 
activated by changing the holding potential from -80 mV to -10 mV for 50 ms with an 
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interval of 10 sec, and the inward currents were recorded. Under these conditions, 
voltage-gated Na+ channels and K+ channels were blocked by TTX, TEA, 4-AP and Cs+, 
and thus the recorded inward currents can be expected to be, for the most part, Ca2+ 
currents. In each experiment, 0.1 mM Cd2+ was added to the bath solution at the end of the 
experiment, and the remaining Cd2+-resistant component was subtracted from the 
depolarization-activated currents to obtain the true Ca2+ currents (Fig. 7A). For 
measurements of Na+ currents, the standard external and internal solutions were used as 
the bath and pipette solutions, respectively. The holding potential was changed from -80 
mV to 0 mV for 5 ms with an interval of 4 sec, and the peak amplitude of inward currents 
was measured. For measurements of K+ currents, 1 M TTX was added to the standard 
external solution. Patch pipettes were filled with the standard internal solution. The 
holding potential was changed from -80 mV to 0 mV for 30 ms with an interval of 4 sec, 
and the peak amplitude of outward currents was measured. To estimate the drug effects, 
three consecutive currents were averaged before, during and after drug application, and 
the averaged value during application was divided by the mean of the values before and 
after application.  
 All experiments were performed at room temperature. Recordings were 
discarded when series resistance was >20 M or >25 M at the beginning or end of 
experiments, respectively, or recovery of current amplitude after drug application was 
less than 70 % of the basal level. Statistical significance of drug actions was assessed by 
Student's paired or unpaired t-test. Single, double and triple asterisks in figures indicate 
p<0.05, p<0.01, p< 0.001, respectively. All data are expressed as mean  SEM. 
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4.3 Drugs.  
Clozapine, NDMC, CNQX and baclofen were purchased from Tocris Cookson (Bristol, 
UK). AMPA and bicuculline were purchased from Sigma-Aldrich (St. Louis, MO), and 
GABA was from Wako (Japan). Clozapine, NDMC and CNQX were dissolved in DMSO 
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Recordings of IPSCs and EPSCs. (A) Schematic drawing showing measurements of 
evoked IPSCs or EPSCs from a pair of neurons having a synaptic connection. IPSCs and 
EPSCs show different decay kinetics. (B) IPSCs are consistently blocked by the GABAA 
antagonist bicuculline (10 M). (C) EPSCs are consistently blocked by 25 M CNQX, an 
AMPA-type glutamate receptor antagonist.  
 
Figure 2 
Both clozapine and NDMC depress IPSCs in a dose-dependent and reversible manner. (A, 
D) The time courses of changes in IPSC amplitudes and IPSC traces (top) from 
representative experiments with 30 M clozapine (A) and NDMC (D). (B, E) Relative 
amplitudes of IPSCs acquired before (C), during (T) and after (R) application of 1, 3 or 30 
M clozapine (B) and NDMC (E). They are normalized to the values before drug 
application. (C, F) Individual (open symbols) and averaged (closed circles) data for the 
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IPSC amplitude in the presence of 1, 3 or 30 M clozapine (C) or NDMC (F). The data 
are normalized to the means of the IPSC amplitudes obtained before and after drug 
application. Open squares, diamonds, and circles are the data from excitatory, inhibitory, 
and unidentified postsynaptic neurons. The number of experiments is indicated in 
parentheses for this and subsequent figures. 
 
Figure 3 
EPSCs are less sensitive to clozapine and NDMC than IPSCs. (A, D) Representative 
examples of the experiments showing effects of 30 M clozapine (A) and NDMC (D). (B, 
E) Relative amplitudes of EPSCs acquired before, during and after application of 3 or 30 
M clozapine (B) and NDMC (E). (C, F) Individual (open symbols) and averaged (closed 
circles) data for the EPSC amplitude in the presence of 3 or 30 M clozapine (C) or 
NDMC (F). Open squares, diamonds, and circles are the data from excitatory, inhibitory, 
and unidentified postsynaptic neurons. 
 
Figure 4 
Both clozapine and NDMC reduce the GABA-induced currents in a reversible manner.  
(A) Schematic drawing showing local application of 10 M GABA to the tested neuron. 
The GABA-induced currents are blocked by 10 M bicuculline. (B, F) Representative 
examples of the experiments showing effects of 30 M clozapine (B) and NDMC (F) on 
GABA-induced currents. (C, G) Relative amplitudes of GABA-induced currents 
acquired before, during and after application of 1, 3 or 30 M clozapine (C) and NDMC 
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(G). (D, H) Individual (open circles) and averaged (closed circles) data for the amplitude 
of GABA-induced currents in the presence of 1, 3 or 30 M clozapine (D) or NDMC (H). 
(E, I) Summary bar graphs showing effects of 1, 3 or 30 M clozapine (E) and NDMC (I) 
on IPSCs and GABA-induced currents. Averaged values shown in Fig. 2C, 2F, 4D and 4H 
are assembled in this figure for comparison. 
 
Figure 5 
Slight potentiation of the AMPA-induced currents by clozapine and NDMC.  (A) The 
currents induced by local application of 50 M AMPA are blocked by 25 M CNQX. (B, 
D) Representative examples of the experiments showing effects of 30 M clozapine (B) 
and NDMC (D) on AMPA-induced currents. (C, E) Left: Relative amplitudes of 
AMPA-induced currents acquired before, during and after application of 30 M clozapine 
(C) and NDMC (E).  Right: Individual (open circles) and averaged (closed circles) data 




Effects of clozapine and NDMC on the paired-pulse ratio of IPSCs and EPSCs. (A) An 
example showing an increase in the paired-pulse ratio during presynaptic suppression 
induced by the GABAB agonist baclofen. Traces acquired before and during application 
of baclofen are superimposed. The traces scaled to the first IPSCs are shown on the right. 
(B) A representative experiment showing an increase in the paired-pulse ratio of IPSCs in 
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the presence of 30 M clozapine. (C, D) Summary data for the paired-pulse ratio (top) 
and the amplitude of IPSCs (C) or EPSCs (D) obtained before, during and after 
application of 30 M clozapine or NDMC. 
 
Figure 7 
Effects of clozapine and NDMC on voltage-gated Ca2+ channels.  (A) Depolarizing 
voltage pulses from -80 to -10 mV for 50 ms induce inward currents (left), which are 
subtracted by the Cd2+-resistant component (middle) to yield Ca2+ currents (right). (B, E) 
Representative examples of the experiments showing effects of 30 M clozapine (B) and 
NDMC (E) on Ca2+ currents. (C, F) Relative amplitudes of Ca2+ currents acquired before, 
during and after application of 3 or 30 M clozapine (C) and NDMC (F). (D, G) 
Individual (open circles) and averaged (closed circles) data for the amplitude of Ca2+ 
currents in the presence of 3 or 30 M clozapine (D) or NDMC (G). 
 
Figure 8 
Effects of clozapine and NDMC on voltage-gated Na+ channels. (A, C) Representative 
examples showing effects of 30 M clozapine (A) and NDMC (C) on inward Na+ 
currents. (B, D) Left: Relative amplitudes of Na+ currents acquired before, during and 
after application of 30 M clozapine (B) and NDMC (D). Right: Individual (open circles) 
and averaged (closed circles) data for the amplitude of Na+ currents in the presence of 30 




Effects of clozapine and NDMC on voltage-gated K+ channels. (A, C) Representative 
examples showing effects of 30 M clozapine (A) and NDMC (C) on outward K+ 
currents. (B, D) Left: Relative amplitudes of K+ currents acquired before, during and after 
application of 30 M clozapine (B) and NDMC (D). Right: Individual (open circles) and 
averaged (closed circles) data for the amplitude of K+ currents in the presence of 30 M 
clozapine (B) or NDMC (D). 
 
Table 1. Series resistance, holding current and input resistance during application of clozapine and NDMC 
  Series resistance (M)  Holding current at -80 mV (pA)  Input resistance (M) 
Drug Before Drug After  Control Drug  Control Drug 
Clozapine  3 M (n=6) 12.9  1.9 13.2  2.0 14.0  2.4  -236  50 -234  50  131  25 131  25 
 30 M (n=9) 13.0  1.4 13.4  1.6 13.6  1.7  -236  42 -211  44**  130  17 139  21 
NDMC  3 M (n=7) 12.1  1.2 13.0  1.8 13.6  2.1  -239  47 -236  48  133  20 132  19 
 30 M (n=9) 12.3  1.1 12.8  1.3 13.1  1.5  -240 40 -206  45**  126  14 148  23* 
* P<0.05, ** P<0.01. 
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